REGENXBIO's GAAP loss for 3 months of 2022 was $76.723 million, up 53% from $50.139 million in the prior year. Revenue increased 17.7% to $22.218 million from $18.884 million a year earlier.
REGENXBIO's GAAP loss for 3 months of 2022 was $76.723 million, up 53% from $50.139 million in the prior year. Revenue increased 17.7% to $22.218 million from $18.884 million a year earlier. 
ir.regenxbio.com
English (US) 